Protembis is an Aachen, Germany based medical device startup. It develops a novel catheter-based filter device for use during cardiac interventions. The device is designed to minimize the risk of stroke and other neurological injury during these interventions – particularly during transcatheter aortic valve replacement procedures (TAVR/ TAVI). The filter blocks embolic debris from entering the blood vessels leading to the brain. The initial safety and feasibility of the ProtEmbo® device has been demonstrated in a first-in-human study in 2017/ 2018. The imaging data of the study suggests that the ProtEmbo® device decreases the risk of brain injury by up to 90%. Protembis has closed an oversubscribed $10M Series A financing round in 2018 and expects to bring its product to market maturity with this round. Therefore the team plans to conduct further clinical studies in heart centers in Europe and the U.S. The ProtEmbo® device is not yet commercially available.